Literature DB >> 2593915

Prolonged hepatic cholestasis after flucloxacillin therapy.

I B Turner1, R P Eckstein, J W Riley, M R Lunzer.   

Abstract

A severe prolonged illness that was characterized by deep jaundice and debilitating pruritus occurred in five patients after the use of flucloxacillin. The symptoms and signs of liver disease took at least two months to resolve; after four- to nine-months' follow-up, liver enzyme activities have remained abnormal in all patients. Examination of liver biopsy specimens showed severe cholestasis in all cases, with evidence of significant bile-duct injury in three cases. In one patient, in whom symptoms have persisted for nine months, examination of a liver biopsy specimen showed marked bile-duct depletion. All patients were seen during a four-month period and it is felt that flucloxacillin-induced liver disease probably has been under-diagnosed and underreported. The use of flucloxacillin has been increasing rapidly and it is anticipated that more cases of flucloxacillin hepatotoxicity will occur in the future.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2593915     DOI: 10.5694/j.1326-5377.1989.tb139652.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

1.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Updated study on risk of cholestatic liver disease and flucloxacillin.

Authors:  Lin Li; Hershel Jick; Susan S Jick
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

3.  Severe cholestatic hepatitis following cloxacillin treatment.

Authors:  S Goland; S D Malnick; R Gratz; E Feldberg; D Geltner; Z M Sthoeger
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

Review 4.  Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?

Authors:  B M Devereaux; D H Crawford; P Purcell; L W Powell; H P Roeser
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Risk factors for development of flucloxacillin associated jaundice.

Authors:  C K Fairley; J J McNeil; P Desmond; R Smallwood; H Young; A Forbes; P Purcell; I Boyd
Journal:  BMJ       Date:  1993-01-23

6.  [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].

Authors:  U Hartmann; S Schmitt; M Reuss-Borst
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 7.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

Review 8.  Drug-induced cholestasis.

Authors:  Vinay Sundaram; Einar S Björnsson
Journal:  Hepatol Commun       Date:  2017-09-11

9.  Successful liver transplantation for drug-induced vanishing bile duct syndrome.

Authors:  Ahmed Hashim; Ashley Barnabas; Rosa Miquel; Kosh Agarwal
Journal:  BMJ Case Rep       Date:  2020-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.